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Abstract
Despite numerous discussions, workshops, reviews and reports about responsible development of nanotechnology,
information describing health and environmental risk of engineered nanoparticles or nanomaterials is severely lack-
ing and thus insufficient for completing rigorous risk assessment on their use. However, since preliminary scientific
evaluations indicate that there are reasonable suspicions that activities involving nanomaterials might have dama-
ging effects on human health; the precautionary principle must be applied. Public and private institutions as well
as industries have the duty to adopt preventive and protective measures proportionate to the risk intensity and
the desired level of protection. In this work, we present a practical, ‘user-friendly’ procedure for a university-wide
safety and health management of nanomaterials, developed as a multi-stakeholder effort (government, accident
insurance, researchers and experts for occupational safety and health). The process starts using a schematic deci-
sion tree that allows classifying the nano laboratory into three hazard classes similar to a control banding
approach (from Nano 3 - highest hazard to Nano1 - lowest hazard). Classifying laboratories into risk classes would
require considering actual or potential exposure to the nanomaterial as well as statistical data on health effects of
exposure. Due to the fact that these data (as well as exposure limits for each individual material) are not available,
risk classes could not be determined. For each hazard level we then provide a list of required risk mitigation mea-
sures (technical, organizational and personal). The target ‘users’ of this safety and health methodology are research-
ers and safety officers. They can rapidly access the precautionary hazard class of their activities and the
corresponding adequate safety and health measures. We succeed in convincing scientist dealing with nano-activ-
ities that adequate safety measures and management are promoting innovation and discoveries by ensuring them
a safe environment even in the case of very novel products. The proposed measures are not considered as con-
straints but as a support to their research. This methodology is being implemented at the Ecole Polytechnique de
Lausanne in over 100 research labs dealing with nanomaterials. It is our opinion that it would be useful to other
research and academia institutions as well.
Introduction
In the last years, nanotechnology has become a key word
of public interest, since it brings together different areas
of science and benefits from an interdisciplinary or “con-
verging” approach and is expected to lead to innovations
that can contribute to addressing many of the problems
facing today’s society. A scientific and technical revolu-
tion has begun that is based upon the ability to systemati-
c a l l yo r g a n i z ea n dm a n i p u l a te matter on the nanometer
length scale. Several nanotechnology-based products
have been marketed including electronic components,
scratch-free paint, sports equipment, wrinkle- and stain-
resistant fabrics, sun creams, and medical products (e.g.
bandages, heart valves, MRI contrast agents). Analysts
estimate that the market for such products is currently
around hundred of billions of euro and could rise to one
trillion by 2015 [1]. Accordingly, potential occupational
and public exposure to manufactured nanoparticles will
increase dramatically in the near future. Many research-
ers have addressed the toxicity issues associated with
different nanoparticles in vitro and in vivo [2-4]. How-
ever, information describing the relative health and envir-
onmental risk assessment of engineered nanoparticles or
nanomaterials (hereafter, we will use ISO/TR 12885 defi-
nition [5] of engineered nanomaterials) is severely lack-
ing. Effects of nanoparticle properties on the immune
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nanoparticle preparations generally fall into two cate-
gories: (a) responses to nanoparticles that are specifically
modified to stimulate the immune system or (b) undesir-
able side-effects of nanoparticles [6]. One initiative that
tried to shed light on this issue is a recently completed
global review of completed and nearly completed envir-
onment, health and safety research on nanomaterials and
nanotechnology [7]. The resulting EMERGNANO report
is a unique attempt to identify and assess worldwide pro-
gress in relation to nanotechnology risk issues. There is
no doubt a consensus among producers and users that
there is “a need for better characterization of nanotech-
nology constructs” and for the production of “reagent-
grade” nanomaterials, which permit comparison between
researches and tests [8]. Recently, this lack of progress in
nanotoxicology came under the spotlight [9] again when
researchers reported that nanoparticles had been found
in the lungs of seven women who had become ill after
working in a paint factory in China; two of them later
died [10]. However, it remains unclear if the illnesses
were caused by the nanoparticles or other chemicals [11].
There is also a widespread agreement [12] that this tragic
accident could have been prevented by proper health and
safety procedures - the women only occasionally wore
masks and the first symptoms appeared five months after
the ventilation unit in the factory broke down. At the
very least what happened in China emphasises the impor-
tance of proper risk management when workers are
exposed to nanoparticles for prolonged periods [9].
Initial safety and health strategies [13-15] were analo-
gies to those for chemicals and powders. Yet, they are
not applied consistently and users and producers seem
to rely mostly on personal protective equipment [16].
More recent efforts aim at developing strategies that tar-
get nano-specific aspects [17-20]. Recently, the Swiss
Government published a precautionary matrix that
allows an initial assessment of the risks of nanomaterial
applications without requiring detailed knowledge on
the toxicology of the nanomaterials involved [21]. Such
preliminary information is essential for simplified, so-
called control-banding approaches that group risks in
broad classes and then define different levels (or bands)
of protection efforts [22].
A professional hazard is any potential source of
damage, injury or harmful effect in respect of a thing or
person in certain conditions of the workplace. A hazard
is a characteristics of something (tool, machine, product,
but also instruction, activity, organization etc..) that can
negatively affect the integrity of a person or thing.
Risks are associated with the nature of material and
exposures that people have to that material. For a full
risk assessment, detailed information is required about
the material (chemical composition of nanoparticles,
Material Safety Data Sheet when available, particle mor-
phology, aspect ratio, particle size distribution, zeta
potential, solubility, known hazards) as well as about the
full process descriptions where nanomaterials are used
or produced. For each uptake route (respiratory organs,
skin, gut) type and level of exposure need to be investi-
gated for each process step. This is a challenge, because
it is unclear which characteristics drive the toxicity of
nanomaterials and thus need to be measured. Several
methods already exist to measure nanoparticle concen-
trations in air. Mobility particle sizers usually provide
reliable and comparable data [23]. However, they are
large, expensive and require extensive training, inducing
hindrances for routine exposure assessment of workers
or researchers.
All this complicates risk assessment considerably.
Nevertheless, given the lack of current knowledge about
the toxicity of nanomaterials, the difficulty to compare
the results obtained from various investigations, and the
concern that the bulk materials’ safety data sheets might
not adequately reflect the real hazardousness of nano-
materials, precaution recommends that all nanomaterials
shall be considered potential l yh a z a r d o u su n l e s ss u f f i -
cient information to the contrary is obtained.
Precautionary principle
At the Rio Conference on the Environment and devel-
opment in 1992, world leaders agreed on the Precau-
tionary principle stated in the following terms: ‘In order
to protect the environment, the precautionary principle
shall be widely applied by states according to their cap-
ability. Where there are threats of serious or irreversible
damage, lack of full scientific certainty shall not be a
reason for postponing cost-effective measures to prevent
environmental degradation’ [24]. While this principle
has primarily been used internationally around environ-
mental health issues, other groups are adopting this phi-
losophy to protect the health of workers. In 1996, the
American Public Health Association passed a resolution
entitled, “The Precautionary Principle and Chemical
Exposure Standards for the Workplace”. This resolution
recognized the need for implementing the precautionary
approach, where chemicals are considered potentially
dangerous, until the extent of its toxicity is sufficiently
known, and the establishment of strict, preventive che-
mical exposure limits. In February 2000, the European
Commission published a Commission Communication
on the precautionary principle (EU Resolution on the
Precautionary Principle, 2000) providing a general fra-
mework for its use in EU policy [25].
So, if a preliminary scientific evaluation emphasizes
that there are reasonable grounds for concern that a
particular activity might lead to damaging effects on the
environment, or on human, animal or plant health, the
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we consider the precautionary principle as directly
applicable to emerging nanotechnologies.
Being responsible for safety and health in an research
institution, we had to determine which actions should
be taken, potential effects of taking no actions, the
uncertainties inherent in the scientific evaluation, and
the views on how to manage the risks. The adopted
measures had to be proportionate to the level of risk
and the desired level of protection and will evolve with
forthcoming knowledge. It is possible that level of pro-
tection may be eased, especially for Nano 3 as defined
here, as more is known about specific nanomaterials.
Objectives and motivation
At EPFL (Ecole Polytechnique Fédérale de Lausanne),
over 30 research groups (in basic sciences, engineering
or life sciences) produce, modify or use engineered
nanomaterials (Figure 1) in approximately 100 labora-
tories with over 300 different associated production or
characterization processes. Classical risk assessment
methods (Hazard and Operability Studies (HAZOP) -
often used to analyze risks in chemical processes, Failure
M o d ea n dE f f e c t sA n a l y s i s( F M E A )-o f t e nu s e di n
industry to evaluate the effects of potential failure
modes, etc.) would require around 2000 man/day work-
load - huge resources, nearly impossible to obtain. Some
other institutions have already developed best practices
guides and safety management procedures for nanoma-
terials [26-29]. However, they mainly propose a risk ana-
lysis approach for each individual process and particle
type, which is not very practical for large research
centers with many different, constantly changing forms
of nano-related studies and laboratories. Or alterna-
tively, good laboratory practices are proposed [30,31]
that apparently are not well respected. Published in the
February issue of Nature Nanotechnology [32], Jesus
Santamaria and his team have conducted an online sur-
vey to identify what safety practices researchers are fol-
lowing in their laboratories. The responses of the 240
participants shed some light on what is going on. The
questions covered: details of the materials and proces-
sing methods used; safety measures; waste disposal pro-
cedure, and knowledge of legislation for handling
nanomaterials. One of the most surprising results [33] is
that nearly three quarters of respondents reported not
having internal rules to follow regarding the handling
nanomaterials (approximately half of them didn’th a v e
rules and over a quarter were not aware of any internal
regulations). All this led to the development of a metho-
dology and procedure helping to answer questions
related to safety and health for present and future users
of nanomaterials in university setting. The methodology
was introduced and tested for applicability at the EPFL.
Development of safety procedure for nanoobjects
production/use
A Nanosafe team consisting of three safety and health
specialists, one nano-health and occupational hygiene
expert, one insurance representative, three EPFL scien-
tists and nanoparticles’ users (production and use) and
one representative of State Secretariat for Economic
Affairs was appointed to develop a procedure for mana-
ging the occupational safety and health risks relevant to
research laboratories producing and using nanomater-
ials. The procedure consists of two parts. Using a deci-
sion tree we sort the “nano-laboratories” into three
hazard classes (Nano 3 = highest hazard to Nano 1 =
lowest hazard), which corresponds to analogue
approaches applied to other hazard types (biohazard,
radioprotection or chemistry). We then provide a list of
required prevention/protection measures (safety bar-
riers) for each hazard level. The target users of this
safety and health methodology are at first researchers.
They can rapidly access the hazard class of their activity
and the corresponding adequate safety and health mea-
sures. More detailed analysis of specific activities can be
undertaken by safety and health experts when needed.
According to our opinion and experience, the proposed
management of nanomaterial safety is not stifling or
harming innovation, as it is sometimes feared among
researchers [34].
Decision tree for laboratory type determination
Figure 2 depicts the questions to be answered by nano-
material users and producers (only research environment
Figure 1 Different forms of nanomaterials produced at the
EPFL. Examples of different forms of nanomaterials produced at the
EPFL. a) Confocal micrograph of cells exposed to Cy3.5 labelled
nanoparticles (red). b) High resolution transmission electron
micrograph of superparamagnetic iron oxide nanoparticles. c)
Optical micrograph of V2O5 nanowires [47]. d) Transmission electron
micrograph of V2O5 nanowires. e) Suspension of gold nanoparticles.
f) Transmission electron micrograph of gold/silica core-shell
nanoparticles. g) Scanning Electron Micrograph of aligned carbon
nanotubes forest [48] h) Transmission Electron Micrograph of
carbon nanotubes produced by Chemical Vapour Deposition.
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when classifying their activities. Exposure to nanomater-
ials may happen by ingestion, inhalation, injection and
dermal contact. The main occupational exposure routes
are the respiration tract and the skin. Consequently, the
first differentiation regards the environment, whether the
process is carried out in a closed (complete process
confinement) or open system. In case the process is not
fully enclosed (glove box or completely sealed environ-
ment), different types of activities with nanomaterials are
subsequently discussed individually.
Activity with nanofibers
The scientific community is mostly concerned about the
toxicity/carcinogenicity of manufactured nanofibers
Activity with 
nanomaterials
Activity with 
NP in 
suspension
Activity
with NP in 
powder 
form
Activity
with NP in 
a matrix
Production
Use
Quantity < 1 mg per 
batch
Quantity 
> 100 mg 
per batch
Quantity < 100 mg 
per batch and > 1 
mg per batch
Quantity > 
10 mg per 
experiment
Quantity < 10 mg 
per experiment 
and > 1 mg per 
experiment
Quantity < 1 mg per 
experiment
At least one 
phase of the 
process can 
release aerosol
Phase of the 
process in closed 
milieu
Phase of the 
process in open 
milieu
At least one phase 
of the process can 
release dry NP
Phase of the 
process in closed 
milieu
Phase of the 
process in open 
milieu
The NP 
remain in 
suspension
Recipient
manipulated  > 
1liter
Recipient
manipulated  <
1liter
Particles 
agglomerate
Activity with 
nanofibers
L/d >3
Dry nanofibers
In suspension
In a matrix
Nano 3 No
Nano 2
Nano 3
Yes
Do not know
Particles 
agglomerate
Nano 2 No
Nano 1
Nano 2
Yes
Do not know
Particles 
agglomerate
Nano 3 No
Nano 2
Nano 3
Yes
Do not know
Particles 
agglomerate
Nano 2 No
Nano 1
Nano 2
Yes
Do not know
Nano 1
Nano 1
Nano 1
Nano 1
Nano 3
Nano 1
Nano 1
Nano 1 
reinforced
Nano 1
Nano 3
Nano 3
Entire process in 
closed milieu
YES
Nano 1
NO
Possibility
to release 
dust
YES
No
Possibility
to release 
dust
No
YES
Figure 2 Decisions tree used for determination of Nano hazard type. Questions to be answered by nanomaterials users and producers
when determining laboratory (Nano hazard) type. NP: nanoparticles, L/d: length - diameter aspect ratio.
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than 3) because of their morphological resemblance to
asbestos. Inhalation of asbestos fibers is known to
induce asbestosis (a progres s i v ef i b r o t i cd i s e a s eo ft h e
lung), lung and pleura cancer. The health hazards of
nanofibers are mostly limited to carbon nanotubes and
are the subject of an intensive research. Results of
already established toxicity studies show a clear mor-
phology-toxicity relationship for carbon nanotubes,
[35,36] as previously observed for asbestos fibers [37].
H o w e v e r ,s y n t h e s i so fn a n o f i b e r si sb e i n gc o n t i n u o u s l y
under progress and, as a result, nanofibers can be made
out of nearly any material nowadays. Some of them will
very likely resemble more closely to asbestos than car-
bon nanotubes by their size, chemical composition or
surface properties. They open the possibility of making
nanofibers with undesired harmfulness [38], which
could be putatively equal or even higher than the one of
asbestos. Hence, all activities, either with dry nanofibers
or nanofibers in suspension will situate the laboratory in
the Nano 3 category (Figure 2) except for those where
nanofibers are strongly interacting with the matrix
(composites), preventing the materials to be released in
the environment (refer to activities with nanoobjects in
solid matrix).
Activity with nanoobjects in powder
The exposure dose is a function of exposure level and
duration of exposure [39]. In traditional risk assessment,
exposure doses are compared to Threshold Limit Values
(TLV). In Switzerland, there are no TLV that were spe-
cifically generated for nanomaterials but there are TLV
[40] for diesel particles (0.1 mg/m
3), and fumed silica
(4 mg/m
3). The British Standards Institute proposed, as
a pragmatic guidance, the following [14]: if a material is
classified in its larger form as carcinogenic, mutagenic,
asthmagenic or a reproductive toxin and a TLV is
known, its nano form will have a TLV 10 times smaller.
For insoluble materials, their nanoform will have a lar-
ger safety margin (1/15 the non-nanoscale TLV); for
soluble materials, it is reduced by a half. These consid-
erations are included in our approach.
For nanopowders we distinguished production and
handling (Figure 2). The lower limit up to which a pro-
duction laboratory is classified in Nano 1 is set to 1 mg
of nanomaterial present at any given moment. If one
assumes a volume of 10 cubic-meters in which particles
could spread around an equipment or a person in case
of incidents, 1 mg corresponds to the TLV for diesel
particles (1 mg/10 m
3 =0 . 1m g / m
3). From a practical
perspective, 1 mg constitutes the lower detection limit
of many common laboratory balances. Laboratories with
more than 1 mg but less than 100 mg are classified as
Nano 2 or Nano 3, depending on the agglomeration sta-
tus. Nanomaterials exhibiting large surfaces might be
toxic or catalyze the production of toxic substances.
Furthermore, nanoparticles often display good transfer
into [41] and across epithelial cells [42] and then distri-
bute to other body compartments probably as a function
of size and surface properties [43]. Thus, laboratories
with single particles or unstable agglomerates are in
Nano 3. Stable agglomerates and aggregates do not have
the nano-specific route of transfer ("normal” transports
can still occur) and are expected to affect health more
like “classical” ambient air pollution particles [44]. Con-
sequently, activities with agglomerates are classified in
Nano 2.
Laboratories using more than 100 mg (a considerable
quantity in a research environment) are always classified
as Nano 3.
For the hazard classification of nanoparticles handling
activities, an identical approach as for production activ-
ities is taken (Figure 2), with the exception that the
upper limit for Nano 3 i sr e d u c e db yaf a c t o rt e n
(10 mg). Very often, particles are supplied by other
laboratories or external suppliers, where occupational
safety and health team cannot control the process as
well as for home-made particles. Furthermore, users
manipulate such particles more often in confined spaces.
Activity with nanoobjects in suspension
Many applications and investigations use nanoparticles
in colloidal suspensions. Nanoparticles in suspension are
rarely encountered as bare nanoparticles but have their
surface modified in order to ensure colloidal stability or
subsequent surface derivatization. This increases the
complexity when determining colloids toxic action.
The hazards related to nanomaterials suspension is
not only influenced by the nature of particles but also
by the dispersant. The decision tree (Figure 2) is orga-
nized accordingly: For manipulated quantities superior
to 1 liter the nature of the used dispersant (flammable,
toxic etc.) is considered equally important: working
under the fume hood is mandatory in laboratories classi-
fied as “reinforced hazard level Nano 1”. If particles
remain in suspension and the manipulated quantity is
smaller than 1 liter, the laboratory is classified Nano 1
(equivalent to a classical chemical lab). If aerosols can
be released, the equipment has to be placed in a closed
environment. Airborne droplets can carry large amounts
of nanoparticles into the lungs, and especially small dro-
plets can dry quickly while the solid parts remain air-
borne. Laboratories with such processes are thus
considered as Nano 3.
Activity with nanoobjects in solid matrix
Studying composites with nanoobjects embedded in
polymer or in ceramic matrices represents one of the
most important activities with nanomaterials at EPFL.
The preparation of composites is either treated as
“Activity with nanoobjects in suspension” or “Activity
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tion or in dry conditions, respectively. The laboratory is
treated as Nano 1 if material characterization and post-
preparation processing activities do not include any
mechanical or thermal treatment. If dust can be released
during the manipulation or if composites are friable,
laboratory is treated as “Activity with nanoobjects in
powder”.
Protective measures
Inhalation and skin contact are considered as most
important exposure routes. Measures are organized in
consequence. Technical, organizational and personal
protective measures for different laboratory (Nano
hazard) types are presented in Figure 3, 4 and 5. Even
though management of cleaning can be considered as a
part of organizational measures, it is separated (Figure 6)
to underline its importance.
Technical measures
As illustrated in Figure 3 laboratories with hazard level
Nano 3 will require rather extensive technical measures
with capture at source, exiting air filtering with at least
a F7 filter [EN 779 -European Standard for ventilation
filters. F7 has 80-90% average efficiency for 0.4 μm par-
ticles], and access restrictions using a security vestibule
(double door). A double security vestibule with a safety
shower is required for each new lab while simple one
can be installed for existing laboratories without suffi-
cient space.
Organizational measures
Most organizational protective measures are similar for
all laboratory types (see Figure 4). Measures not listed
in the figure are the following:
- Each laboratory must have a responsible person
(nano-officer).
- An ordering/receiving procedure must be established
with identified collecting points.
- Pregnant women are allowed to work with nanoma-
terials only with a special work authorization issued by
an occupational physician.
- Lab safety audits are performed by occupational
health and safety specialists.
- Permanent laboratory staff working in Nano 2 lab
and every person working in Nano 3 are subject to med-
ical surveillance On this question, reports [45] indicate
that level of knowledge today doesn’t allow proposing a
specific medical survey, or indicators of exposure or
effects. Still, certain consensus is obtained at interna-
tional level [46] to recommend that potentially exposed
workers should have periodical medical survey with
‘conventional’ exams, specific for potential target organ.
One can think about respiratory tract or cardiovascular
system. Results of these medical exams can also be
source for data base to make epidemiological studies
afterwards.
Personal measures
Personal protective measures (see Figure 5 as well as
Figure 7) assign specific equipments to different hazard
levels. As example, a mask with Powered Air Respirator
must be used if the work lasts over two hours (Nano 3),
while P3 (EN 143) or FFP3 (EN 149)/P-100 (USA
NIOSH) filter/filtering mask is accepted for shorter
work periods. Protection of body parts depends on the
hazard level. Two pairs of adapted protective gloves are
mandatory when working in Nano 2 and above.
Cleaning management
Only Nano 1 laboratories can be cleaned by the regular
(external) cleaning staff (see Figure 6) wearing protec-
tive equipment adapted to work in a chemical labora-
tory. Nano 2 must be cleaned by specially trained
(external) personnel wearing the same protective equip-
ment as lab employees and under the supervision of the
Nano 1 Nano 2 Nano 3
Ventilation Chemistry lab type (renewal without recycling 5-10 X/h) x x x
With at least sealed F7 filter (maintenance!) for exiting air x
Low pressure in the room x x > 20 mPa
Capture at source x x
Floor Flooring Resin
Manipulation under fume hood Optional x (1)
Compulsory x x
Access restriction Restricted (magnetic card access control system) x x
Regular lab access control (laboratory key) x
Evidence about exposed people + board to record presence x
SAS entrance and exit Double SAS (if > 100 g ultrafine particles) x
Simple SAS (is < 100 g ultrafine particles) Light SAS x
Safety shower x
Use of vacuum cleaners  Asbestos type x x x
Housekeeping type
Measures
Laboratory
T
e
c
h
n
i
c
a
l
Tiling or linoleum
Forbidden
Figure 3 Technical safety measures. Technical safety actions
applied to laboratory classified ‘Nano’. (1) Reinforced type 1 = type
1 plus obligatory manipulation under fume hood.
Nano 1 Nano 2 Nano 3
Restricted access Authorized persons only x x
Only activities nano in the laboratory x
Training Written working procedures x x x
Basic training x x x
Continuous training x x
City/laboratory clothes separation  x
Conditioning of material  Toxic (trash bin for toxic) x x x
contaminated by nano Double bag for toxic waste (100 microns thickness) x x x
Storage of bags in a sealed container x x x
Elimination of nano substances  Liquid waste
and products Solid waste
Waste and PPE evacuation Domestic waste treatment channel
Special waste treatment channel x x x
Transports of "nano-objects" Simple packaging
Double packaging x x x
Measures
Laboratory
O
r
g
a
n
i
z
a
t
i
o
n
a
l
Double packaging
Forbidden
Forbidden
Figure 4 Organizational safety measures. Organizational safety
actions applied to laboratories classified ‘nano’.
Nano 1 Nano 2 Nano 3
Eyes protection Safety glasses x
Laboratory mask or close fitting safety goggles x x
Respiratory organs protection Mask with assisted ventilation x
FFP3 mask x if < 2 h
Body protection Overal with hood - Tyvek style  x
Non-woven lab coat x
Simple lab coat x
Overshoes x x
Hands protection 2 pairs of adapted gloves x x
1 pair of adapted gloves x
Measures
Laboratory
P
e
r
s
o
n
a
l
Figure 5 Personal safety measures. Personal safety actions
applied to laboratories classified ‘nano’.
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the lab employees themselves wearing the same perso-
nal protective equipment as for working and under
supervision of a lab responsible. Only in exceptional
cases, trained external personnel can be allowed to
clean in Nano 3 laboratories under the supervision of
the nano-officer.
Conclusions
Present knowledge on nanomaterial toxicity is insuffi-
cient for completing precise risk assessment. Threshold
Limit Values for nanomaterials do not exist nor is there
standard equipment for sufficiently detailed routine
exposure measurements. However, since preliminary
scientific evaluations show that there are reasonable
grounds for concern that activity with nanomaterials
might have damaging effects on human health; the pre-
c a u t i o n a r yp r i n c i p l em u s tb ea p p l i e d .H e r ew ep r o p o s e
practical, clear and simple procedure for Nano safety
and health management, which is a general approach
based on the state of the nanomaterial in question
(fibers and particles as powder, suspension, or in a solid
matrix). New hazard knowledge will be used as it is
developed and made available. The procedure proposes
pragmatic mitigation measures that laboratories have to
take for limiting exposures as much as considered rea-
sonable. The lab responsible is in charge of applying
measures adapted to specific activities. The proposed
methodology and protective measures are provisional in
nature pending the availability of more reliable scientific
data. The procedure also allows estimating the number
of research groups working in high hazard level labora-
tories. For reducing investment and operating cost,
activities that classify laboratories into the highest
hazard level should be centralized as much as possible.
The methodology is being implemented at the Ecole
Polytechnique de Lausanne in over 100 research labs
dealing with nanomaterials;e v a l u a t i o no fi t sp e r f o r -
mance will be done when sufficient data are available.
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